Background Image
Previous Page  143 / 156 Next Page
Information
Show Menu
Previous Page 143 / 156 Next Page
Page Background

141

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

217

Mercadante S, Villari P, Ferrera P, Mangione S, Casuccio A. The use of opioids for break-

through pain in acute palliative care unit by using doses proportional to opioid basal

regimen. Clin J Pain 2010; 26(4): 306-309.

218

Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A. Safety and effec-

tiveness of intravenous morphine for episodic breakthrough pain in patients receiving

transdermal buprenorphine. J Pain Symptom Manage 2006; 32(2): 175-179.

219

Mercadante SL, Berchovich M, Casuccio A, Fulfaro F, Mangione S. A prospective rando-

mized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients.

Am J Hosp Palliat Care 2007; 24(1): 13-19.

220

Miyazaki T, Hanaoka K, Namiki A, Ogawa S, Kitajima T, Hosokawa T, Ishida T, Nogami S,

Mashimo S. Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing

matrix transdermal patch system in Japanese patients with cancer pain. Clin Drug Investig

2008; 28(5): 313-325.

221

Miyazaki T, Namiki A, Ogawa S, Kitajima T, Masuda Y, Iwao Y, Uchida E, Iseki M, Matoba

M, Hashizume T. [A phase II clinical study of once-a-day fentanyl citrate patch in patients

with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day

fentanyl citrate patch]. Gan To Kagaku Ryoho 2010; 37(9): 1747-1752.

222

Moksnes K, Dale O, Rosland JH, Paulsen O, Klepstad P, Kaasa S. How to switch from

morphine or oxycodone to methadone in cancer patients? A randomised clinical phase II

trial. Eur J Cancer 2011; 47(16): 2463-2470.

223

Moos, R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with

an emphasis on bisphosphonates. Support Care Cancer 2008; Oct;16 (10): 1105-15,

(Review).

224

Moryl N, Kogan M, Comfort C, Obbens E. Methadone in the treatment of pain and termi-

nal delirum in advanced cancer patients. Palliat Support Care 2005; 3(4): 311-317.

225

Moulin DE, Richarz U, Wallace M, Jacobs A, Thipphawong J. Efficacy of the sustained-

release hydromorphone in neuropathic pain management: pooled analysis of three

open-label studies. J Pain Palliat Care Pharmacother 2010; 24(3): 200-212.

226

Murino P, Mammucari M, Borrelli D, Pepe A, Giugliano MF, Morra A, Panelli G, Manzo R,

Ravo V, Muto P. Role of immediate-release morphine (MIR) in the treatment of predictab-

le pain in radiotherapy. J Pain Palliat Care Pharmacother 2011; 25(2): 121-124.

227

Murphy BA, Beaumont JL, Isitt J, Garden AS, Gwede CK, Trotti AM, Meredith RF, Epstein

JB, Le QT, Brizel DM, Bellm LA, Wells N, Cella D. Mucositis-related morbidity and resource

utilization in head and neck cancer patients receiving radiation therapy with or without

chemotherapy. J Pain Symptom Manage 2009; 38(4): 522-532.

228

Mystakidou K, Katsouda E, Kouloulias V, Kouvaris J, Tsiatas M, Vlahos L. Comparison of

transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for

the management of metastatic bone pain. J Opioid Manag 2005; 1(4): 204-210.

229

Nadstawek J, Leyendecker P, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K. Patient

assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int

J Clin Pract 2008; 62(8): 1159-1167.

Literaturverzeichnis